Breast Cancer

, Volume 19, Issue 3, pp 253–258

Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study

  • Masataka Sawaki
  • Hirofumi Mukai
  • Nahomi Tokudome
  • Takahiro Nakayama
  • Naruto Taira
  • Toshiro Mizuno
  • Yutaka Yamamoto
  • Akiyo Horio
  • Toru Watanabe
  • Yukari Uemura
  • Yasuo Ohashi
Original Article

DOI: 10.1007/s12282-011-0270-9

Cite this article as:
Sawaki, M., Mukai, H., Tokudome, N. et al. Breast Cancer (2012) 19: 253. doi:10.1007/s12282-011-0270-9

Abstract

Background

For targeting anti-HER-2, trastuzumab-incorporated chemotherapy is the standard for HER-2-overexpressing breast cancer in adjuvant settings. But there are few data on trastuzumab in elderly patients. We evaluated the incidence of adverse events among an elderly population of trastuzumab-treated HER-2-positive breast cancer patients in adjuvant settings.

Methods

Data on 39 elderly HER-2 overexpressing breast cancer patients treated with both curative surgery and adjuvant trastuzumab were retrospectively collected from a Japanese multicenter study. The loading dose was 8 mg/kg body weight, and the maintenance dose was 6 mg/kg every 3 weeks; or the loading dose was 4 mg/kg followed by 2 mg/kg weekly as maintenance.

Results

After a median follow-up of 20.0 (2.4–53.9) months, a total of 32 patients (82.1%) completed 1-year trastuzumab treatment. The median treatment duration was 12.0 months (range 2–12; mean 10.5). Adverse events occurred in 11 patients (28.2%). Four (10.2%) discontinued or interrupted treatment after experiencing toxicity. One patient died because of interstitial pneumonia. Three patients (7.7%) had congestive heart failure (CHF), one of whom had a history of angina. Three patients (7.7%) had a lower left ventricular ejection fraction (LVEF), and brain natriuretic peptide elevation was totally observed in three patients (7.7%). Three patients with lower LVEF had received chemotherapy containing doxorubicin before trastuzumab. Of the three patients, two discontinued therapy because of CHF, but all recovered with proper medication containing a diuretic agent.

Conclusions

Elderly patients tolerated trastuzumab well, although careful management is needed.

Keywords

Breast cancer HER-2/neu Trastuzumab Elderly 

Copyright information

© The Japanese Breast Cancer Society 2011

Authors and Affiliations

  • Masataka Sawaki
    • 1
  • Hirofumi Mukai
    • 2
  • Nahomi Tokudome
    • 3
  • Takahiro Nakayama
    • 4
  • Naruto Taira
    • 5
  • Toshiro Mizuno
    • 6
  • Yutaka Yamamoto
    • 7
  • Akiyo Horio
    • 8
  • Toru Watanabe
    • 9
  • Yukari Uemura
    • 10
  • Yasuo Ohashi
    • 10
  1. 1.Department of Clinical Oncology and ChemotherapyNagoya University Graduate School of MedicineNagoyaJapan
  2. 2.Department of Oncology and HematologyNational Cancer Center Hospital EastChibaJapan
  3. 3.Department of Medical OncologyCancer Institute Hospital of Japanese Foundation for Cancer ResearchTokyoJapan
  4. 4.Department of Breast and Endocrine SurgeryOsaka University HospitalOsakaJapan
  5. 5.Department of Breast and Endocrine SurgeryOkayama University HospitalOkayamaJapan
  6. 6.Department of Medical OncologyMie University HospitalTsuJapan
  7. 7.Department of Breast and Endocrine Surgery, Graduate School of Medical SciencesKumamoto UniversityKumamotoJapan
  8. 8.Department of Breast OncologyAichi Cancer Center HospitalNagoyaJapan
  9. 9.Department of MedicineHamamatsu Oncology CenterShizuokaJapan
  10. 10.Department of Biostatistics, School of Public HealthUniversity of TokyoTokyoJapan

Personalised recommendations